The research of our laboratory is focused on understanding the cellular and molecular mechanisms that govern immune tolerance in the context of allergic inflammation. Our previous studies have uncovered the TGF-β superfamily member, activin-A, as a novel inducer of CD4+Foxp3-IL-10-producing regulatory T cells that suppress Th2 cell-driven allergic responses in vivo (Semitekolou et al JEM 2009). Activin-A-induced regulatory T cells also protect against experimental asthma upon transfer in vivo. This beneficial effect is associated with dramatically decreased maturation of draining lymph node dendritic cells (DCs). We are interested in elucidating the mechanisms involved in the generation and suppressive function of activin-A-induced regulatory T cells; the roles these cells play in the induction of tolerogenic DCs and the maintenance of immune homeostasis in the respiratory mucosa, and their effects on the development of other regulatory T cell subsets (‘infectious tolerance’). Understanding of the mechanisms that induce regulatory T cell suppression may offer critical insight into how their function may be exploited in vivo for the design of effective immunotherapies.
For these studies, our laboratory employs a wide range of immunological analyses including in vitro cellular techniques and in vivo animal models of allergic diseases. In addition, biochemical and molecular biology approaches along with genomics (such as RNA-Seq analyses), proteomics and mass spectrometry analyses are utilized.
Asthma is a serious chronic disease characterized by airway hyperresponsiveness (AHR) and inflammation. Current therapeutic approaches fail to provide a cure, mainly in individuals with severe asthma associated with established airway remodeling. Vascular changes are central components of airway remodeling and relate to increased airway wall thickness, AHR and asthma severity. Hence, factors that can effectively control airway vascular remodeling represent essential therapeutic targets. We have previously shown that activin-A is increased in a mouse model of chronic airway remodeling and in the lungs of asthmatics at baseline and following pulmonary allergen challenge in vivo (Kariyawasam HH et al J Allergy and Clin Immunol 2009, Kariyawasam HH et al, Am J Respir Crit Care Med, 2008). In addition, activin-A promotes human airway epithelial cell repair and decreases inflammatory cytokine and chemokine release in vitro. Our current research aims to elucidate the role of activin-A and its downstream signaling pathways in the regulation of airway remodeling and angiogenic processes in chronic allergic airway disease in vivo and in severe asthmatics.